A small-scale study has confirmed that 18F-FDG PET scans on pregnant women deliver lower-than-expected radiation doses to the fetus.
A small-scale study has confirmed that 18F-FDG PET scans on pregnant women deliver lower-than-expected radiation doses to the fetus. The study, published this month in theJournal of Nuclear Medicine, was led by Amol Takalkar, MD, of the LSU Health Sciences Center and the Biomedical Research Foundation of Northwest Louisiana in Schreveport.
The retrospective analysis considered five pregnant women with malignancies (two with cervical cancer, two with lymphoma, and one with lung cancer) confirmed through biopsy. All underwent PET-only (no CT) studies with a reduced 18F-FDG dose (173.9 to 340.4 MBq rather than the standard 555 MBq), with the exception of one patient whose pregnancy test was negative immediately before the procedure, who received 583.12 MBq. The patients were given vigorous hydration to minimize radiation exposure to the fetus.
Researchers reviewed six 18F-FDG PET studies (one woman had two studies done), one in early pregnancy, one in the second trimester, and three in the third trimester. The fetal dose exposure from 18F-FDG PET studies was estimated to range from 1.1 to 2.43 mGy for various trimesters in pregnancy (except for the patient in the early stage of pregnancy, in whom activity in the whole uterus was considered, and the fetal dose was estimated to be 9.04 mGy). All patients delivered healthy infants with no visible abnormalities at term.
The researchers concluded that the radiation dose from 18F-FDG PET scans was “quite low and significantly below the threshold for deterministic effects due to radiation exposure to the fetus.”
In addition, Takalkar and colleagues found that the estimated fetal radiation exposure in these five cases was slightly lower than existing estimates on fetal dose exposure, and that, if confirmed by future studies, current fetal dose estimates may need revision.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.